Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$19.45
-5.2%
$18.78
$12.21
$41.31
$571.44M-0.2598,432 shs404,073 shs
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
$8.01
-1.2%
$8.31
$6.10
$28.67
$554.73M1.6403,117 shs341,746 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$4.88
-2.2%
$5.51
$3.72
$12.61
$555.62M1.911.26 million shs881,190 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.56
+3.5%
$14.08
$5.22
$27.38
$158.11M0.41139,789 shs143,572 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+2.45%+1.99%+19.51%+27.06%-14.46%
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-5.70%+9.15%+21.04%-34.17%-64.07%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-2.73%+6.35%+17.14%-38.70%-32.11%
LifeVantage Co. stock logo
LFVN
LifeVantage
+2.28%+1.08%-14.21%-37.35%+79.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
3.241 of 5 stars
4.43.00.00.02.51.70.6
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
3.8372 of 5 stars
4.43.00.00.02.64.20.6
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.363 of 5 stars
4.40.00.00.03.90.00.6
LifeVantage Co. stock logo
LFVN
LifeVantage
3.9651 of 5 stars
3.51.01.72.72.11.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.70
Moderate Buy$35.8884.45% Upside
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
2.70
Moderate Buy$25.00212.11% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.75
Moderate Buy$14.29192.74% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50142.83% Upside

Current Analyst Ratings Breakdown

Latest LFVN, BCYC, ANAB, and COGT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.00
5/6/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$52.00 ➝ $54.00
5/5/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $17.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.00
5/2/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/1/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
5/1/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.00
4/9/2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/26/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Johnson Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$111.87M5.11N/AN/A$3.32 per share5.86
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
$25.72M21.57N/AN/A$12.35 per share0.65
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$2.30 per shareN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.71$0.66 per share19.03$2.38 per share5.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%N/A
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-$180.66M-$3.14N/AN/AN/A-450.64%-27.35%-20.81%N/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$192.41M-$1.84N/AN/AN/AN/A-112.55%-60.44%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6922.43N/A3.46%34.29%15.04%N/A

Latest LFVN, BCYC, ANAB, and COGT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.56-$0.52+$0.04-$0.52N/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/5/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million
5/1/2025Q1 2025
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million
2/27/2025Q4 2024
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.61-$0.72+$0.89-$0.72$10.17 million$43.11 million
2/25/2025Q4 2024
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
-$0.85-$0.75+$0.10-$0.75$5.47 million$3.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.43%N/A26.09%2 Years

Latest LFVN, BCYC, ANAB, and COGT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
10.23
10.23
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
N/A
17.13
17.13
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
6.44
6.44
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
86.15%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.70%
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
22.90%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
5.92%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.38 million20.17 millionOptionable
Bicycle Therapeutics plc stock logo
BCYC
Bicycle Therapeutics
24069.25 million63.18 millionOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80113.86 million103.92 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable

Recent News About These Companies

LifeVantage Declares Quarterly Dividend
LifeVantage: Activation Of Shareholder Value
LifeVantage (LFVN) Receives a Buy from Lake Street

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$19.45 -1.07 (-5.21%)
As of 04:00 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Bicycle Therapeutics stock logo

Bicycle Therapeutics NASDAQ:BCYC

$8.01 -0.10 (-1.23%)
As of 04:00 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$4.88 -0.11 (-2.20%)
As of 04:00 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.56 +0.43 (+3.54%)
As of 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.